机构:[1]Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Dept Gynecol, Guangzhou 510060, Guangdong, Peoples R China[2]First Peoples Hosp Yunnan Prov, Dept Gynecol, Kunming 650032, Peoples R China外科片妇科云南省第一人民医院[3]Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Dept Med Affairs, Guangzhou 510060, Guangdong, Peoples R China
Aberrant activation of the Wnt/beta-catenin signal pathway is frequently observed in various human cancers. Therefore, it was speculated that adenomatous polyposis coli 2 (APC2) could play important roles in activating the Wnt/b-catenin pathway. In this present study, miR-939 expression was markedly upregulated in ovarian cancer tissues and ovarian cancer cells. In functional assays, Overexpression of miR-939 promoted the proliferation and anchorage-independent growth of ovarian cancer cells, whereas inhibition of miR-939 inhibited this effect. Bioinformatics analysis further revealed APC2, a putative tumor suppressor as a potential target of miR-939. Result of luciferase reporter assays showed that miR-939 directly binds to the 30-untranslated region (30-UTR) of APC2 mRNA. Furthermore, we demonstrated that miR-939 could reduce the Wnt/b-catenin signal pathway by suppressing APC2 directly, resulting in increasing expression of CyclinD1, MYC and TCF. In functional assays, APC2-silenced in miR-939-in-transfected ES-2 cells have positive effect to promote cell proliferation, suggesting that direct APC2 downregulation is required for miR-939-induced ovarian cancer cell proliferation. In sum, our data provided compelling evidence that miR-939 functioned as a potential tumor promoter by regulating the Wnt/b-catenin signal pathway through direct suppression of APC2 expression and might sever as a potential therapeutic target for ovarian cancer patients. (C) 2015 Elsevier Masson SAS. All rights reserved.
基金:
Department of Gynecology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类|4 区医学
小类|4 区医学:研究与实验4 区药学
最新[2023]版:
大类|2 区医学
小类|1 区药学2 区医学:研究与实验
JCR分区:
出版当年[2014]版:
Q3PHARMACOLOGY & PHARMACYQ3MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
第一作者机构:[1]Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Dept Gynecol, Guangzhou 510060, Guangdong, Peoples R China[*1]Department of Gynecology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, No. 651, Dongfengdong Road, Guangzhou 510060, People’s Republic of China
通讯作者:
通讯机构:[1]Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Dept Gynecol, Guangzhou 510060, Guangdong, Peoples R China[*1]Department of Gynecology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, No. 651, Dongfengdong Road, Guangzhou 510060, People’s Republic of China
推荐引用方式(GB/T 7714):
Xiong Ying,Qi Li-ya,Zhou Feng,et al.MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression[J].BIOMEDICINE & PHARMACOTHERAPY.2015,71:64-69.doi:10.1016/j.biopha.2015.02.020.
APA:
Xiong Ying,Qi Li-ya,Zhou Feng,Wang Yin&Liu Ji-hong.(2015).MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression.BIOMEDICINE & PHARMACOTHERAPY,71,
MLA:
Xiong Ying,et al."MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression".BIOMEDICINE & PHARMACOTHERAPY 71.(2015):64-69